Date: August 13, 2026
Ref. No.: KDL/SE/028/2026-27

To,	To,
BSE Limited	**National Stock Exchange of India Limited**
Corporate Relationship Department	Exchange Plaza, Plot No. C-1, Block G,
25th Floor, Phiroze Jeejeebhoy Towers	Bandra Kurla Complex, Bandra (East)
Dalal Street, Mumbai- 400001	Mumbai – 400051
Scrip Code: 543328	**NSE Symbol:** KRSNAA

Subject: Press Release – Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Press Release on the Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2026.

Request you to take the same on your records.

Thanking you,
Yours sincerely,

For **Krsnaa Diagnostics Limited**

Sujoy Sudipta Bose
Digitally signed by Sujoy Sudipta Bose
Date: 2026.08.13 23:47:24 +05'30'

Krsnaa Diagnostics Limited

Sujoy Sudipta Bose
Company Secretary and Compliance Officer
Encl: As above

KRSNAA DIAGNOSTICS LTD.

Q1 FY2027 RESULTS | PRESS RELEASE

Promoters Back the Platform: Krsnaa Approves Preferential Warrant Issue as Revenue Grows 22% and Rajasthan Goes Live

Pune, August 13, 2026: Krsnaa Diagnostics Ltd. (BSE: 543328 | NSE: KRSNAA), one of India's leading integrated diagnostic service provider, today announced its financial and operating performance for the quarter ended June 30, 2026.

Revenue from operations grew 22% YoY to ₹2,355 million, reflecting continued growth in the established business alongside contributions from newly commissioned projects. Like-for-like projects grew approximately 12% YoY.

(Rs. Million)	Q1 FY2027	Q1 FY2026
Revenue from Operations	2,355	1,930
EBITDA	588	524
EBITDA Margin %	25%	27%
Profit After Tax (PAT)	166	205
PAT Margin %	7%	11%

Rajasthan goes live: The Rajasthan pathology network transitioned from implementation to operations during the quarter. By quarter-end, 31 mother labs, 62 hub labs and 1,228 collection centres were operational, contributing ₹257 million of revenue in Q1. The moderation in margins is primarily a function of the upfront fixed cost base of Rajasthan laboratories, equipment, manpower and logistics being carried ahead of full utilisation. This is the normal rhythm of an infrastructure-led model: investment and costs come first, and revenue follows as utilisation builds.

Retail accelerates: Retail revenue grew approximately 64% YoY and 22% sequentially to ₹193 million, with the retail network expanding to more than 4,250 touchpoints across five states.

Promoters reaffirm confidence: The Board approved the issue of share warrants to the Promoter and Promoter Group, subject to applicable approvals and regulatory requirements.

Other operating highlights: 8 of 17 planned MRI centres in Maharashtra were inaugurated and made operational during the quarter; 12 new NABH accreditations were added; Apulki-Pune hospital commenced operations; and Krsnaa secured a new CT project award in Himachal Pradesh for 34 CT scanners.

Commenting on the results, Mr. Yash Mutha, Managing Director, said: "Q1 FY2027 reflects the growing strength of the platform we have built. Our existing business continues to grow, while Rajasthan and other new projects are adding a second layer of growth. With retail scaling rapidly and our newly commissioned infrastructure moving towards higher utilisation, we remain focused on converting the platform we have built into sustainable, long-term value for our shareholders."

Mr. Mitesh Dave, Group Chief Executive Officer, said: "Q1 was a quarter of execution converting infrastructure into live, revenue-generating capacity. Rajasthan is now operational, our retail network has crossed 4000 + touchpoints and our radiology footprint continues to expand. As utilisation builds across these investments, we expect the operating leverage inherent in our model to become increasingly visible."

About Krsnaa Diagnostics: Krsnaa Diagnostics Ltd. is a differentiated diagnostic services provider across Radiology and Pathology. The Company operates across 19 states and Union Territories with more than 4,000 centres nationwide, serving patients through its integrated diagnostic, technology and logistics platform. Its guiding philosophy is “Let’s Do Good…”.